|
| 37060036 | Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial. | Breast Cancer Res | 2023 |
| 35526835 | Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer. | J Mol Diagn | 2022 |
| 34238931 | Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. | NPJ Breast Cancer | 2021 |
| 33547330 | The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. | Sci Rep | 2021 |
| 32124136 | Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. | Breast Cancer Res Treat | 2020 |
| 31999296 | High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 31723001 | Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. | Cancer Res | 2020 |
| 31721395 | Heart failure after treatment for breast cancer. | Eur J Heart Fail | 2020 |
| 32706636 | Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. | J Clin Oncol | 2020 |
| 32146256 | Prognosis of acute coronary syndromes after radiotherapy for breast cancer. | Radiother Oncol | 2020 |
| 30385276 | Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. | Int J Radiat Oncol Biol Phys | 2019 |
| 31302855 | Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. | Breast Cancer Res Treat | 2019 |
| 31186341 | Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-<i>BRCA1/2</i> breast cancer families. | J Med Genet | 2019 |
| 30748011 | Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. | Int J Cancer | 2019 |
| 30580169 | Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. | Breast | 2019 |
| 30606886 | Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer. | Oncologist | 2019 |
| 30588619 | Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. | Int J Cancer | 2019 |
| 29063679 | Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. | Mol Oncol | 2018 |
| 29917140 | Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. | J Natl Cancer Inst | 2018 |
| 29806795 | Long-term outcomes of bilateral direct-to-implant breast reconstruction in women at high breast cancer risk. | J Plast Surg Hand Surg | 2018 |
| 29885375 | Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. | Eur J Cancer | 2018 |
| 30065254 | Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. | Br J Cancer | 2018 |
| 30420699 | Pathway-based subnetworks enable cross-disease biomarker discovery. | Nat Commun | 2018 |
| 29700408 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. | Sci Rep | 2018 |
| 29635145 | Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. | Eur J Cancer | 2018 |
| 29633761 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. | Nat Commun | 2018 |
| 29230665 | Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. | Breast Cancer Res Treat | 2018 |
| 27612322 | Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant. | Mod Pathol | 2017 |
| 28412587 | Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. | Eur J Cancer | 2017 |
| 28494403 | HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. | Eur J Cancer | 2017 |
| 28346508 | Most women recover from psychological distress after postoperative complications following implant or DIEP flap breast reconstruction: A prospective long-term follow-up study. | PLoS One | 2017 |
| 28283652 | <i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. | Cancer Res | 2017 |
| 29546343 | Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. | J Natl Cancer Inst | 2017 |
| 29232439 | Body mass index and breast cancer survival: a Mendelian randomization analysis. | Int J Epidemiol | 2017 |
| 29059683 | Association analysis identifies 65 new breast cancer risk loci. | Nature | 2017 |
| 29058716 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. | Nat Genet | 2017 |
| 29031778 | Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. | Lancet Oncol | 2017 |
| 29116004 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. | Breast Cancer Res | 2017 |
| 29262523 | <i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. | Oncotarget | 2017 |
| 28649643 | Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. | NPJ Breast Cancer | 2017 |
| 28732650 | Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2017 |
| 25940428 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. | Gynecol Oncol | 2016 |
| 27764697 | Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. | Neoplasia | 2016 |
| 27755534 | Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. | Br J Cancer | 2016 |
| 27836010 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. | Breast Cancer Res | 2016 |
| 27601076 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. | Nat Commun | 2016 |
| 27600471 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). | Sci Rep | 2016 |
| 27595995 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. | J Med Genet | 2016 |
| 27149063 | RAD51B in Familial Breast Cancer. | PLoS One | 2016 |
| 27269948 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. | J Clin Oncol | 2016 |